Cargando…
Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
SLPI has been implicated in the progression and metastasis of certain cancers. However, the effects of SLPI seem to be tumor-specific and the mechanisms remain poorly defined. Here, we demonstrate that highly metastatic, triple-negative breast cancer (TNBC) 4T1 cells secreted more SLPI compared to t...
Autores principales: | Kozin, Sergey V., Maimon, Nir, Wang, Rong, Gupta, Nisha, Munn, Lance, Jain, Rakesh K., Garkavtsev, Igor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752445/ https://www.ncbi.nlm.nih.gov/pubmed/29312532 http://dx.doi.org/10.18632/oncotarget.22660 |
Ejemplares similares
-
SLPI: a new target for stopping metastasis
por: Munn, Lance L., et al.
Publicado: (2018) -
Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
por: Dickey, Brittney L., et al.
Publicado: (2021) -
Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression
por: Wex, Thomas, et al.
Publicado: (2011) -
Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells
por: Sayers, Kevin T., et al.
Publicado: (2014) -
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022)